Mangoceuticals, Inc. (MGRX)
NASDAQ: MGRX · Real-Time Price · USD
2.140
-0.240 (-10.08%)
Mar 31, 2025, 10:47 AM EDT - Market open
Mangoceuticals Revenue
In the year 2024, Mangoceuticals had annual revenue of $615.87K, down -15.81%. Mangoceuticals had revenue of $105.25K in the quarter ending December 31, 2024, a decrease of -56.93%.
Revenue (ttm)
$615.87K
Revenue Growth
-15.81%
P/S Ratio
7.65
Revenue / Employee
$205,291
Employees
3
Market Cap
11.06M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 615.87K | -115.62K | -15.81% |
Dec 31, 2023 | 731.49K | 722.55K | 8,083.16% |
Dec 31, 2022 | 8.94K | - | - |
Dec 31, 2021 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionMGRX News
- 2 months ago - Mangoceuticals, Inc. Executes Exclusive Distribution Agreement with Propre Energie for Clinically Proven Dermytol®️ Skincare Treatment Targeting Hyperpigmentation - GlobeNewsWire
- 3 months ago - Mangoceuticals, Inc. Completes Acquisition of Mushroom-Based Wellness and Innovations Patent - GlobeNewsWire
- 5 months ago - MangoRx Responds to and Refutes Recent Claims Made by Eli Lilly - GlobeNewsWire
- 5 months ago - Mangoceuticals, Inc. Announces Participation at the Centurion One Capital 2nd Annual Bahamas Summit 2024 - Newsfile Corp
- 6 months ago - MANGOCEUTICALS, INC. ANNOUNCES 1-FOR 15 REVERSE STOCK SPLIT AS PART OF NASDAQ COMPLIANCE PLAN - GlobeNewsWire
- 6 months ago - MangoRx Introduces Oral Tirzepatide GLP-1 Receptor Agonist for Advanced Weight Loss Solutions - GlobeNewsWire
- 6 months ago - MangoRx Addresses $49.3 Billion Global GLP-1 Market With Launch of Oral Semaglutide for Advanced Weight Loss Treatment - GlobeNewsWire
- 8 months ago - MangoRx Reports 1,685% Increase in Shareholders' Equity From December 31, 2023, to $13.8MM, and 56% Increase in Year-Over-Year Revenue for First Half of 2024 - GlobeNewsWire